IS THE FRENCH LISTE-EN-SUS STILL SUPPORTING ACCESS TO INNOVATIVE MEDICINES?

被引：0

|

作者：

Ortiz, I ^{[1
]}

Conti, C. ^{[1
]}

Furniss, S. J. ^{[2
]}

机构：

[1] GfK, London, England

[2] GfK, Melton Mowbray, England

来源：

VALUE IN HEALTH | 2014年 / 17卷 / 07期

关键词：

D O I：

10.1016/j.jval.2014.08.962

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PHP27

引用

收藏

页码：A409 / A409

页数：1

相关论文

共 3 条

[1] A NEW METHODOLOGY TO DEFINE THE SCOPE OF THE FRENCH LISTE-EN-SUS
Motte, A.
Mourlat, B.
Kujas, P.
Eliaszewicz, M.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A515 - A515
[2] LISTE-EN-SUS REFORM IN FRANCE - WHAT ARE THE CONSEQUENCES?
Mitrano, M.
Flostrand, S.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A538 - A538
[3] "Liste en sus", Early Access to Innovation, ATU (Pre-Approval Access) ... Towards an Essential New Deal. From a Clinician's Perspective
Metges, J. P.
[J]. ONCOLOGIE, 2017, 19 (11-12) : 386 - 389